T he "worldwide explosion in the prevalence of type 2 diabetes mellitus 1 " has turned diabetes into a global epidemic. 2 Epidemiological data have shown that diabetes prevalence skyrocketed in rec c cent years; for example, in the US, a 61% increase in the prevalence of diabetes between 1990 and 2001 has been reported. 2 The prevalence of precdiabetes, defined as impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT), is also increasing globally. 1, 3 Recent studies 2 have shown precdiabetes which eventuc c ally progresses to diabetes in up to 70% of cases, to be a risk factor for cardiovascular disease. 2 It follows that there is a critical need to develop efc c fective methods to improve early detection and treatc c ment of diabetes and precdiabetes, in an effort to avert the wellcknown complications of diabetes. These mic c croc and macrovascular complications continue to claim more lives and to further exhaust national budgets. Control of hyperglycemia, as monitored by glycated hec c moglobin (HbA 1c ), has been recommended by various international diabetes organizations which recommend Hemoglobin A 1c (HbA 1c ) has been used for decades to monitor the control of glycemia in diabetes. Although HbA 1c is currently undergoing a reassessment, and major developments have been underway in recent years, HbA 1c is not recommended at present for diabetes screening or diagnosis. The objec--tive of this review is to summarize the recent developments and to review a potential diagnostic role for HbA 1c . Implementation of changes in HbA 1c results and units of measurements have been suggested for the purpose of test standardization. These include lower reference ranges (by about 1.5-2 points) and measurement units expressed in percentage (%), as mg/dL (mmol/L) or mmol/mol (or a combination of these units). In diabetes screening and diagnosis, the current diagnostic guidelines use measurement of plasma glucose either fasting or after glucose load. These diagnostic methods have shortcomings war--ranting a potential diagnostic role for HbA 1c . While recent developments in HbA 1c methodologies are acknowledged, it is not yet known which changes will be implemented, and how soon. Given the recent literature supporting HbA 1c diagnostic abilities, and given the shortcomings of the current guidelines, it is possible that a diagnostic role for HbA 1c may be considered in future practice guidelines, globally. Very recently, the first of such recommendations has been proposed by an expert panel, as announced by the US Endocrine Society.
HbA 1c management targets. 4 These targets vary from one organization to another, ranging roughly between 6.0% and 7.0%. 4 It is notable, however, that HbA 1c has been associc c ated with controversies and confusion among patients and physicians alike. Among the scientific community, HbA 1c has traditionally served as an indicator of glycec c mic control over the preceding 2c to 3c month period. In the real world, patients with diabetes measure their glucose levels at home obtaining results such as "120 or 200" (mg/dL), while physicians measure HbA 1c with different results that many patients cannot fully comc c prehend, e.g., 7.6% or 8.8%. Among the diabetes scienc c tific community, the main controversies about HbA 1c concern standardization of the test and artifactual inc c terferences with some assay methods. 5 Another controversy about HbA 1c is whether or not the test can be used for screening or diagnosis of diabetes. The current screening and diagnostic methods for diabetes have known shortcomings, which warrant the consideration of HbA 1c as a possible alternative. 5c7 These shortcomings are: 1) the fasting plasma glucose (FPG), the main screening method, suffers from inc c adequate sensitivity; 2) the oral glucose tolerance test (OGTT), a suggested alternative diagnostic test, is considered cumbersome and is not commonly used in clinical settings; 3) both tests require fasting, which may not be feasible, especially in busy clinical settings and in population screening.
In response to the aforementioned concerns, there have been major developments in HbA 1c methodologies and terminologies over the last few years. Similarly, there have been developments regarding a potential diagnosc c tic role for HbA 1c , revisiting this controversial issue. In the forthcoming sections, we will provide an overview of these developments and discuss the validity of HbA 1c as a potential diagnostic test for diabetes.
HbA 1c Terminology and Methodology, Past and Present

The chemistry and clinical interpretation of HbA 1c
During unrelated work in the late 1960s, Rahbar disc c covered a glycated species of hemoglobin that he called the "diabetic hemoglobin" as reported by Miedema. 8 Different subtypes of these compounds have since been described. The collective overall entity, previously termed glycosylated hemoglobin, is referred to in modern laboc c ratory terms as glycated hemoglobin (GHb), but that term or glycosylated hemoglobin is not used commonly at present in cinical settings and dayctocday communic c cation among health care providers. Hemoglobin A1 (HbA1) is a derivative of adult hemoglobin (HbA), with monosaccharide (fructose or glucose) attachments. HbA 1c is the major and the most extensively studied subtype of the three known HbA1 species (HbA1a, b and c). In strict chemical terms, the molecular strucc c ture of HbA 1c is _cNc(1cdeoxy)cfructosylchemoglobin 8 or Nc(1cdeoxyfructosec1cyl) hemoglobin beta chain. 9 HbA 1c is formed via a posttranslational nonenzymatic attachment of glucose to hemoglobin 10 in an irreversible fashion and at a rate dependent on the ambient blood glucose during the lifespan (120 days) of the red blood cell. 8 Hence, HbA 1c is traditionally looked at as an indic c cator of the mean blood glucose (MBG) in the preceding 2 to 3 months. However, it has been recently recognized that the MBG in the preceding 1 to 2 months is the mac c jor contributor to HbA 1c . 11c13 In this regard, it has been found that MBG in the preceding 30 days has the largest contribution to HbA 1c , 11 and that up to 70% is deterc c mined by the preceding 2cmonth MBG. 12 According to Tahara et al, monthly contributions of MBG to HbA 1c are as follows: 50% from the most recent 30 days and 25% from each of the preceding 30 and 60 days. 13 This concept has been referred to as the "weighted" average of blood glucose as related to HbA 1c . 23 Early assay methods measured and reportc c ed different glycated fractions (total GHb, HbA1, and HbA 1c ). 10 This heterogeneity in reported results caused concerns about reliability and reproducibility of HbA 1c . The call for test standardization was critic c cal. In response, the DCCT method (Rex 70 ioncexc c change HPLC) was recommended by the National Glycohemoglobin Standardization Program (NGSP) as the preferred method for US laboratories in the mid 1990s. 10, 24 Compliance with this program was reported to be very satisfactory, as noted in Figure 1 . 10 Outside the US, the NGSP standardization method has been adopted rather universally, but local (somewhat similar) standardization programs have recently been adopted in Sweden 25 and Japan. 26 At about the same time that the NGSP initiated its program, the International Federation of Clinical Chemistry (IFCC) developed the so called "definitive reference method", which was aimed toward global HbA 1c standardization. 8, 10, 23 This method involves a sophisticated technical, 2cstep proc c cedure that further purifies the HbA 1c assay by removc c ing impurities from the tested blood samples. 8 It should be noticed that the NGSP and IFCC results are very tightly correlated (r=0.99), as noted in Figure 2 . These concerns were real and they certainly needed to be addressed. While interfering substances raise conc c cerns about test reliability, recent technologies have inc c troduced more accurate commercial analyzers into clinc c ical use reportedly not affected by common hemogloc c binopathies or uremeia. 33, 34 It is prudent that physicians be aware of the functionality of analyzers used in their local laboratories. They should also be aware of recent circulatory changes that may influence HbA 1c , such as a recent blood transfusion or hemolytic anemia. Finally, in regards to the potential effects of race or ethnicity on HbA 1c measurements, a recent study by Herman et al (n=3819) has addressed this issue. 31 In this study of individuals with IGT, mean HbA 1c was found to be slightly higher in minority US indic c viduals, with the highest differences observed between Caucasians and African Americans (5.8% vs 6.2%, rec c spectively). Therefore, this should be taken into conc c sideration when analyzing HbA 1c results.
Confusing terminologies and measurement units
As anecdotally observed, the fact that the HbA 1c test includes hemoglobin (literally and by name) has often created confusion among patients. While they underc c stand that "diabetes is a disease of blood sugar", they wonder what hemoglobin (referred to as blood count by patients) has to do with diabetes? One of our pac c tients once referred to HbA 1c as "that sugar thing on the blood count"! Similarly 
Summary of the Recent Developments in
HbA 1c Terminology, Methodology and Units of Measurements
Technical and laboratory developments
To capture the aforementioned developments in HbA 1c testing, various national and international laboratory organizations participated in collaborating and then reporting these developments. After a series of expert consensus meetings 10 it was agreed that the proper scic c entific name for the measurement (test) should be "hec c moglobin beta chain (blood) c Nc(1cdeoxyfructosc1c yl) hemoglobin beta chain; substance fraction millmole per mole". This change in HbA 1c units, i.e., mmol/mol, will give totally different HbA 1c numbers that are unc c familiar to clinicians, and therefore we opted not inc c clude these new units in this review. Readers can learn more about this in a brief and concise recent editorial by Panteghini and John. 35 Other changes agreed upon are summarized in the final consensus statement by the aforementioned organizations, and will be reviewed in a subsequent section. 35 The main purpose of the study was to firmly define the relationship between HbA 1c and MBG. Although this correlation had long been obc c served in the literature, the concern was that this corc c relation was not "exceptionally robust", and that prior studies had not utilized frequent glucose measurec c ments.
Clinical Developments (The International
HbA 1c -MBG Study) To better understand the relationship of HbA 1c and glucose levels, an international, multicenter, prospecc c tive study was designed. This landmark study was sponsored by major national and international diabec c tes organizations.
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The most important message from the study sponc c sors during the conduct of the study is that the ultic c mate purpose of the study was to alleviate the patient confusion about HbA 1c terminology and measurement units. 36 Thus, if a tight correlation between HbA 1c and MBG is confirmed, then HbA 1c can be expressed in glucose units, the so called estimated average glucose (eAG), or A 1c cderived average glucose (ADAG).
The study was launched in 2004, and utilized monthly HbA 1c , continuous glucose monitoring sysc c tems and 7cpoint capillary (fingerstick) glucose profiles, and has just been published. 37 The study enrolled 507 subjects: 268 with type 1 diabetes mellitus, 159 with type 2 diabetes mellitus and 80 noncdiabetic controls. As expected, the study confirmed the tight correlation between HbA 1c and average glucose, per linear regresc c sion analysis (P<.0001).
The firmly established tight correlation between HbA1c and a average glucose across the spectrum of glycemia (from normal to extreme hyperglycemia) allowed calculation of an estimated average glucose (eAG) from HbA 1c results. 37 Thus this calculation can be used to express the results of HbA1c measurements into glucose units that patients are more familiar with, i.e., the same units they get from their glucose meters. An easy formula 37 was derived from the study results as follows: eAG (mg/dl)=28.7×HbA 1c %-46.7.
It is notable that of the anticipated changes in HbA 1c measurement, the idea of cocreporting eAG with HbA 1c is not totally new in clinical practice. In fact, many laboratories have been doing that for some time, 38 4 . If the ongoing "average plasma glucose study" fulc c fills its a prioricspecified criteria, an ADAG value calculated from the A 1c result will also be reported as an interpretation of the A 1c results (As noted above, the study has already been completed and published).
Glycemic goals appearing in clinical guidelines
should be expressed in IFCC units (i.e., mmol/ mol), derived NGSP (i.e., %) units, and as ADAG (i.e., mg/dl or mmol/L).
The Role of HbA 1c in Screening and Diagnosis of Diabetes and Pre-diabetes
HbA 1c and MBG correlation from a diagnostic pers s spective: Review of the literature on the diagnostic validity of HbA 1c
Evidence had shown a satisfactory correlation between MBG and HbA 1c 39c42 in the hyperglycemic range. It is exc c pected that such evidence will be firmly substantiated by the International HbA 1c cMBG Study which was recently published. 37 The next question, in regards to the diagnostic issue, was: Does HbA 1c follow glycemia as it transits from normal to precdiabetes and then to diabetes? Research has shown this to be the case indeed. Correlation between HbA 1c and MBG did hold true in cohort large studies, inc c cluding two separate analyses from the populationcbased NHANES (National Health and Examination Survey), the NHANES III and the IV. 43, 44 Certainly, the latest inc c ternational HbA 1c cMBG 37 substantiated this (tight) corc c relation across the glycemic spectrum.
It is notable that the diagnostic role of HbA 1c is not a new research endeavor. As a matter of fact, this issue was addressed soon after GHb discovery, but has rec c mained controversial. 43 In a brief search of the literature since the late 1970s, we came across numerous studies that addressed the validity of HbA 1c for screening and diagnosis, in both type 2 diabetes 45c61 and gestational diabetes mellitus (GDM).
62c71 These studies were hetc c erogeneous in design and yielded no consensus on the diagnostic validity of HbA 1c , overall. An extensive literac c ture search for all relevant studies or appraisal of these studies is beyond the scope of this review. However, we identified published reports that reviewed the available studies in an incdepth scrutiny.
In the case of type 2 diabetes, Perry and associates discussed the ongoing debate about HbA 1c diagnostic usefulness, and analyzed large population studies, as compared to their study, the Early Diabetes Intervention Program (EDIP). 54 They reported that two large epidec c miological studies showed poor sensitivities of HbA 1c , as compared to FPG alone. This was in contrast to the findings of the EDIP study, 54 as well as the findings of two other large, populationcbased studies which showed improved sensitivity of combined HbA 1c and FPG; their own study yielded a sensitivity of 61% for the combined tests versus 45% for FPG alone. 54 Ko et al reported simic c lar advantages of combined HbA 1c and FPG in diabetes screening. 51 Acknowledging that several studies on HbA 1c diagc c nostic validity were done prior to test standardization, Bennett et al recently published a systematic review of studies done between 1998 and 2004. 5 They evaluated primary crosscsectional studies on the accuracy of HbA 1c (at a cutcoff point of 6.1%) for the detection of type 2 diabetes using the OGTT as the reference standard and FPG (at a cutcoff point of 6.1 mmol/L) as a comparison. They cited a total of 63 studies, and included 9 that fulc c filled their strict inclusion criteria; 6 were Asian studies and the rest were from Europe and the US. The findings of the systematic review showed that both HbA 1c and FPG are equally effective screening tools for the detecc c tion of type 2 diabetes, but both were not effective for detection of IGT (sensitivities ~ 50%). At certain cutcoff points of HbA 1c (6.1%) and FPG (6.1 mmol/L), senc c sitivities and specificities were 78% to 81% and 79% to 84% for HbA 1c , and 48% to 64% and 94% to 98%, rec c spectively. 5 The investigators concluded that both HbA 1c and FPG were equally effective screening tools.
Overall, Bennett et al concluded that while HbA 1c may be more expensive than FPG at present, HbA 1c provides less intracindividual variability and better prec c dicts diabetic complications, and thus provides a more favorable argument for costceffectiveness. Additional benefits of HbA 1c included the convenience of nonc fasting, availability of pointcofccare capillary assays, and the potential for mass population screening given the availability of transporting capillary samples from rec c mote areas to central laboratories. 5 While the investigac c tors emphasized the several advantages of HbA 1c over FPG and OGTT, they also recapitulated the possible influences of hemoglobinopathies, uremia, and medicac c tions on HbA 1c measurements. 5 Not included in the systematic review were several studies that addressed the use of HbA 1c in the retroc c spective opportunistic detection of undiagnosed diac c betes in inpatient and outpatient settings.
50c57,60,72 The most impressive report is the recent analysis of the NHANES 1999c2004 cohort reported by Buell et al in late 2007. 44 In this study (n=4935; 3280 normal, 1485 with IFG, and 170 with diabetes), a cutcpoint HbA 1c of 5.8% was shown to have a sensitivity and specificity of 86% and 92%, respectively, for diagnosing diabetes. 44 The final question in regards to the diagnostic vac c lidity of HbA 1c is: What is a reliable HbA 1c cutcpoint for screening and diagnosis? We found out that various cutcpoints have been utilized, and these ranged from 5.8% to 6.2%. 5, 43, 44, 54 Bennett et al concluded in their systematic review that this value was noted to be 6.1% in most reviewed studies. However, they emphasized that there was an argument for a populationcspecific, demographiccadjusted optimum HbA 1c diagnostic cutc off point. 5 Obviously, this cutcoff is arbitrary and will encounter pitfalls in terms of false positives and false negatives; an ideal diagnostic test for diabetes, with high sensitivity and specificity, is desirable but is yet to be found. However, HbA 1c has a good biological varic c ability as compared to FPG (2% vs 14%) and is free of laboratory variability. 19 and is not standardized. However, these recommended guidelines for diabetes screening are not usually followed in rouc c tine clinical practice. 6, 72 Ealovega and associates evaluc c ated retrospective opportunistic screening for diabetes in a large managed care system (n=5752), to evaluc c ate how physicians acted on abnormal glycemic tests done either for targeted screening purposes or as part of routine tests. While 69% of the patients in the sysc c tem were screened, the most commonly used test was RBS (95%), followed by FPG (3%), HbA 1c (2%), whole blood glucose measurement (1%), and GTT (< 1%). Unfortunately, follow up on these tests was uncommon, and therefore the yield from these opportunistic screenc c ing efforts was low. 72 Finally, a survey was conducted by an independent survey company at the 2005 American College of Physicians Annual Meeting. 6 Of 258 phyc c sicians attending the meeting who were surveyed, 93% reported that they routinely screened for diabetes. HbA 1c was the screening or diagnostic method in 49% and 59% of the time, respectively. Interestingly, 49% of these physicians thought that HbA 1c was an approved test for screening. 6 For GDM, GCT is generally adopted in the US as a screening test. It has been noticed that in other places physicians use other screening methods. For example, in the Netherlands, both RBS and GCT are almost equalc c ly used in screening for GDM. 75 We have also observed use of RBS for screening in pregnancy elsewhere.
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Problems with the current diagnostic guidelines For type 2 diabetes and GDM, the current diagnostic methods are suboptimal. The FPG has been shown to have poor sensitivity, missing a significant proportion of subjects with OGTTcconfirmed diabetes, ranging from 33% to 50% 5, 54, 77 in the case of type 2 diabetes. The OGTT on the other hand has been regarded as inconvenient and cumbersome, and not wellcreproc c ducible. 5, 54 From anecdotal observation, the OGTT is particularly inconvenient for pregnant women, mainly due to the unpleasant taste of the glucose load used in the test. Furthermore, both of these glucose tests rec c quire fasting; this requirement is less easily achievable in busy practices and, in particular, in settings of popuc c lation screening. Therefore it is not surprising that these "established diagnostic criteria for diabetes are not followed in the community". 6 Given the aforemenc c tioned arguments, we believe that HbA 1c may provide a reasonable alternative or adjunct in the screening and diagnosis of diabetes. In the case of GDM in particuc c lar, we believe that HbA 1c provides a more tolerable alternative than the unpleasant glucose load tests, if research confirms its diagnostic validity. 78c81 and immediate feedback can thus be provided to patients. This pointc ofccare technology has been shown to improve manc c agement outcomes in patients with diabetes. The adc c vantages of sharing the results of HbA 1c with patients at the time of their visit include better motivation by patients, and better chances that patient take more acc c tive roles in their diabetes management . In addition to its role in diabetes management, we believe that this new pointcofccare technology, especially the most rec c cent improved devices (small, cheap, simple and fast) will be helpful should HbA 1c attain a diagnostic role in diabetes. 5, 81 This will be of particular importance in populationcbased diabetes screening globally, espec c cially the advantage of transporting capillary samples from remote areas. 82 It was reported that: "only in Japan was HbA 1c used for screening or diagnosis of diabetes at present". The consensus was that: "many physicians are already using HbA 1c for the screening and/or diagnosis of diabetes, but differc c ent cutoff levels are being used." The consensus asc c cribed multiple advantages, and fewer disadvantages, to HbA 1c as a diagnostic test. 82 Whether the ADA, or other diabetes organizations, will be revisiting their diagnostic guidelines in regards to HbA 1c remains to be seen. The US Endocrine Society announced in a press release that an expert panel recommended new diagnostic guidelines for diabetes. These recommenc c dations, recently published, 6 noted that the current ADA diagnostic guidelines were made over a decade ago, dismissing HbA 1c as a diagnostic tool based on inadequate test standardization. Given recent evic c dence, the expert panel believed that it was time to revisit using HbA 1c and include it in screening and diagnosis of diabetes. 6 These new guidelines recomc c mended incorporating HbA 1c into the current criteria for screening and diagnosing diabetes, besides FPG and OGTT. The guidelines recommended a screening HbA 1c cutcpoint of 6.0% as a threshold for close folc c low up, and diagnostic cutcpoint of 6.5%, if supported by any glucose test. The guidelines recommended, and for the first time, adding RBS for screening purposes, at a cutcpoint of 130 mg/dl.
Conclusions
In conclusion, HbA 1c has been and continues to be used to monitor the control of glycemia in diabetes managec c ment. While HbA 1c testing will probably not be abanc c doned, it is expected to undergo some changes in terms of terminologies and measurement units. It is anticic c pated that laboratories around the world will either use NGSP % or IFCC (mmol/mol or %) plus MBG (to be called eAG or ADAG) in communicating HbA 1c rec c sults. In the US, it is anticipated that laboratories will probably continue to report NGSP HbA 1c % units, and probably not IFCC (in % units) new units, which are about 2 points lower and may thus cause confusion. Similarly it is not anticipated that the IFCC molar units (mmol/mol), which are quite unfamiliar to clinicians, will be adopted in the US, to avoid further confusion, but this remains to be seen. Changes in other countries that may want to report the IFCC units are expected to be very slow in view of anticipated technical difficulties in achieving such a major transition.
Furthermore, it is anticipated that diabetes organic c zations may consider adding HbA 1c at an appropriate cutcpoint value as a screening tool for diabetes. This has been rationalized by improved test standardizac c tion, and by the observation that a lot of physicians already use HbA 1c for screening of type 2 diabetes, and probably for diagnosis confirmation in some cases. The ES has announced in a press release that an expert panel recommended using HbA 1c in diabetes screening and diagnosis. Whether other diabetes organizations will follow suit remains to be seen.
